When and where will Viatris be presenting at the UBS Global Healthcare Conference?

The UBS Global Healthcare Conference is scheduled for November 12, 2024, at 8:45 a.m. PT.

What is the format of Viatris' presentations at the upcoming conferences?

Viatris will participate in a fireside chat format with executives at both conferences.

When is the Jeffries London Healthcare Conference and what time will Viatris participate?

The Jeffries London Healthcare Conference will take place on November 21, 2024, at 10:30 a.m. GMT.

How can interested parties access the presentations made by Viatris at the conferences?

Both events will be available for live webcasts on Viatris' investor relations website, with archived versions accessible later.

What is the primary mission of Viatris Inc. as described in the announcement?

Viatris Inc. is a global healthcare company that bridges the divide between generics and branded medicines, focusing on providing access to high-quality medicines worldwide.

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference

10/29/24 9:00:00 AM ET

$VTRS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VTRS alert in real time by email

PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the company will participate in two upcoming healthcare conferences.

Details of the presentations can be found below:

UBS Global Healthcare Conference

Date: Tuesday, November 12, 2024
Time: 8:45 a.m. PT / 11:45 a.m. ET
Location: Terranea Resort in Rancho Palos Verdes, California
Format: Fireside chat with Viatris executives

Jeffries London Healthcare Conference

Date: Thursday, November 21, 2024
Time: 10:30 a.m. GMT / 5:30 a.m. ET
Location: Waldorf Hilton Hotel in London, England
Format: Fireside chat with Viatris executives

Interested parties can access live webcasts of both events at investor.viatris.com. An archived version also will be available following the live event and can be accessed at the same location for a limited time.

About Viatris

Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter).

View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-to-participate-in-the-ubs-global-healthcare-conference-and-jefferies-london-healthcare-conference-302290043.html

SOURCE Viatris Inc.

Get the next $VTRS alert in real time by email

Recent Analyst Ratings for

$VTRS

Date	Price Target	Rating	Analyst
7/19/2024	$15.00	Buy	Jefferies
10/23/2023	$13.00 → $9.00	Neutral → Underperform	BofA Securities
6/23/2023	$11.00	Equal Weight → Underweight	Barclays
4/24/2023	$11.00	Overweight → Equal Weight	Barclays
2/17/2023	$16.00 → $14.00	Outperform → Market Perform	BMO Capital Markets
1/27/2023	$13.00 → $15.00	Hold → Buy	Jefferies
11/10/2022	$9.00 → $12.00	Sell → Neutral	UBS
11/8/2022	$10.00	Underweight → Neutral	Piper Sandler

More analyst ratings

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference

Chat with this insight

Q&A

When and where will Viatris be presenting at the UBS Global Healthcare Conference?

What is the format of Viatris' presentations at the upcoming conferences?

When is the Jeffries London Healthcare Conference and what time will Viatris participate?

How can interested parties access the presentations made by Viatris at the conferences?

What is the primary mission of Viatris Inc. as described in the announcement?

Recent Analyst Ratings for $VTRS

$VTRS SEC Filings

SEC Form DEFA14A filed by Viatris Inc.

SEC Form DEF 14A filed by Viatris Inc.

Viatris Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

$VTRS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

Director Malik Rajiv sold $2,334,716 worth of shares (200,000 units at $11.67), decreasing direct ownership by 22% to 505,838 units (SEC Form 4)

Director Malik Rajiv sold $1,195,075 worth of shares (100,000 units at $11.95) (SEC Form 4)

$VTRS Large Ownership Changes

This live feed shows all institutional transactions in real time.

$VTRS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$VTRS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

SEC Form SC 13G/A filed by Viatris Inc. (Amendment)

SEC Form SC 13G filed by Viatris Inc.

SEC Form SC 13G/A filed by Viatris Inc. (Amendment)

Jefferies resumed coverage on Viatris with a new price target

Viatris downgraded by BofA Securities with a new price target

Viatris downgraded by Barclays with a new price target

Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

$VTRS Market Insights

Live Market Insights

Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?

Jefferies Reinstates Buy on Viatris, Announces $15 Price Target

Reported Thursday, Calliditas Therapeutics And Viatris Initiate Phase III Clinical Trial Of Nefecon For IgA Nephropathy In Japan

$VTRS Financials

Live finance-specific insights

Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024

Viatris Reports Second Quarter Financial Results for 2024

Viatris Announces Second Quarter 2024 Dividend

$VTRS Leadership Updates

Live Leadership Updates

Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors

Viatris Appoints Corinne Le Goff as Chief Commercial Officer

Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer

$VTRS Press Releases

Fastest customizable press release news feed in the world

Viatris Named to Forbes' World's Top Companies for Women 2024 List

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

Recent Analyst Ratings for
$VTRS

$VTRS
SEC Filings

$VTRS
Insider Trading

$VTRS
Large Ownership Changes

$VTRS
Analyst Ratings

$VTRS
Insider Purchases

$VTRS
Market Insights

$VTRS
Financials

$VTRS
Leadership Updates

$VTRS
Press Releases